BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Federal Trade Commission
Farmers Insurance
Cantor Fitzgerald

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,958,951

« Back to Dashboard

Which drugs does patent 5,958,951 protect, and when does it expire?

Patent 5,958,951 protects GABITRIL and is included in one NDA. There have been two Paragraph IV challenges on Gabitril.

This patent has twenty-four patent family members in twenty-one countries.

Summary for Patent: 5,958,951

Title: Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride
Abstract:The present invention provides R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride in its pure and stable anhydrous form.
Inventor(s): Ahrndt; Preben (.O slashed.lstykke, DK), Petersen; Henning B.o slashed.rge (Lyngby, DK), Chang; Vincent H. (Lake Forest, IL), Allen; Kimberly Ann (Silver Lake, WI), Cain; Michael H. (Grayslake, IL)
Assignee: Novo Nordiskials (Bagsvoerd, DK)
Application Number:08/872,380
Patent Claim Types:
see list of patent claims
Compound; Process; Formulation; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
CephalonGABITRILtiagabine hydrochlorideTABLET;ORAL020646-005Apr 16, 1999ABRXYesNo► Subscribe► Subscribe► Subscribe
CephalonGABITRILtiagabine hydrochlorideTABLET;ORAL020646-001Sep 30, 1997ABRXYesYes► Subscribe► Subscribe► Subscribe
CephalonGABITRILtiagabine hydrochlorideTABLET;ORAL020646-002Sep 30, 1997ABRXYesNo► Subscribe► Subscribe► Subscribe
CephalonGABITRILtiagabine hydrochlorideTABLET;ORAL020646-003Sep 30, 1997ABRXYesNo► Subscribe► Subscribe► Subscribe
CephalonGABITRILtiagabine hydrochlorideTABLET;ORAL020646-004Sep 30, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,958,951

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark0661/96Jun 14, 1996

International Patent Family for Patent: 5,958,951

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office0906309► Subscribe
Spain2181002► Subscribe
South Korea20000016580► Subscribe
Norway985809► Subscribe
Japan2000511909► Subscribe
Israel127469► Subscribe
Hungary9904035► Subscribe
Poland190858► Subscribe
Norway316889► Subscribe
Poland330424► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
US Army
Johnson and Johnson
Queensland Health
Express Scripts
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: